Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,169 | $57.52 | $182,280.88 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,460 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.855 to 57.82, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,371 | $56.05 | $357,094.55 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,629 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.69 to 56.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · derivative · entry 7 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,563 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,759 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,167 Underlying: Common Stock · 4,759 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 391 | $59.27 | $23,174.57 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · nonDerivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 1,610 | $58.40 | $94,024.00 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.06 to 59.01, inclusive. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 4,529 | $57.54 | $260,598.66 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,301 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.05 to 58.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| December 31, 2020 Filed Dec 31, 2020 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 4,759 | $7.80 | $37,120.20 |
DisclosureSEC source: 0001209191-20-065774 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| December 31, 2020 Filed Jan 1, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-065773 · doc4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 31, 2020 Filed Jan 1, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 638 | $59.27 | $37,814.26 |
DisclosureSEC source: 0001209191-20-065773 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 31, 2020 Filed Jan 1, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,386 | $58.25 | $371,984.50 |
DisclosureSEC source: 0001209191-20-065773 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.04 to 59.00, inclusive. Read SEC document |
| December 31, 2020 Filed Jan 1, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 7,976 | $57.56 | $459,098.56 |
DisclosureSEC source: 0001209191-20-065773 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,024 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.04 to 58.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 31, 2020 Filed Jan 1, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-20-065773 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,520 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · derivative · entry 15 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,520 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F10 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 8,869 | $59.65 | $529,035.85 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 12 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.49 to 59.99, inclusive. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 7,651 | $59.20 | $452,939.20 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 11 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,787,049 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.48 to 59.46, inclusive. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,520 | $0.33 | $5,451.60 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 10 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · derivative · entry 15 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 1,700 | $60.12 | $102,204.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 12 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.045 to 60.13, inclusive. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 13,300 | $59.55 | $792,015.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.94 to 59.83, inclusive. Read SEC document |
| December 30, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,790 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · derivative · entry 14 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,520 Underlying: Common Stock · 16,790 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F10 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,700 | $60.73 | $103,241.00 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 9 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.26 to 61.05, inclusive. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 6,834 | $59.42 | $406,076.28 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779,880 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.21 to 60.01, inclusive. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 8,256 | $58.87 | $486,030.72 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786,714 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.21 to 59.20, inclusive. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,790 | $0.33 | $5,540.70 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · derivative · entry 14 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 1,853 | $61.32 | $113,625.96 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.19 to 61.475, inclusive. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,922 | $60.72 | $420,303.84 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,853 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.11 to 61.075, inclusive. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,225 | $59.48 | $370,263.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.013 to 59.86, inclusive. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · derivative · entry 13 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,310 Underlying: Common Stock · 16,250 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F10 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 100 | $63.41 | $6,341.00 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,500 | $62.60 | $93,900.00 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778,280 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.14 to 63.13, inclusive. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,108 | $61.48 | $68,119.84 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779,780 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.14 to 61.74, inclusive. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 13,542 | $60.71 | $822,134.82 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,780,888 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.12 to 61.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 16,250 | $0.33 | $5,362.50 |
DisclosureSEC source: 0001209191-20-065602 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · derivative · entry 13 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 200 | $63.95 | $12,790.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 2,258 | $63.33 | $142,999.14 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.896 to 63.84, inclusive. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,735 | $62.04 | $231,719.40 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.68 to 62.492, inclusive. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 8,807 | $60.89 | $536,258.23 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,193 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.54 to 61.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 28, 2020 Filed Dec 31, 2020 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-20-065603 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-065257 · doc4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 378 | $65.39 | $24,717.42 |
DisclosureSEC source: 0001209191-20-065257 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,741 | $64.29 | $240,508.89 |
DisclosureSEC source: 0001209191-20-065257 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.01 to 64.63, inclusive. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 7,394 | $63.71 | $471,071.74 |
DisclosureSEC source: 0001209191-20-065257 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.00 to 63.99, inclusive. Read SEC document |
| December 24, 2020 Filed Dec 29, 2020 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 3,487 | $62.15 | $216,717.05 |
DisclosureSEC source: 0001209191-20-065257 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,513 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.81 to 62.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.